PELD Creatinine (Pediatric End-Stage Liver Disease)

Why use it

Incorporating creatinine into the pediatric PELD formula improved the predictive accuracy for 90-day waitlist mortality, particularly in children with acute liver failure, hepatorenal syndrome, and those requiring intensive care. The updated formula aligns the pediatric allocation system more closely with the adult MELD framework, reducing inequality in organ allocation decisions. Accurate PELD calculation at listing and at each update is critical for fair organ allocation and timely transplantation before irreversible deterioration.

About

The Pediatric End-Stage Liver Disease (PELD) score is the primary organ allocation tool for children with liver disease awaiting transplant. The original PELD formula, validated by McDiarmid and colleagues (2002), uses serum albumin, total bilirubin, INR, age at listing (<1 year), and growth failure. An updated UNOS/OPTN policy introduced in 2017 incorporated serum creatinine into the pediatric formula — paralleling the creatinine component in the adult MELD score — recognizing that hepatorenal syndrome and renal impairment independently worsen prognosis in pediatric liver disease. This PELD with creatinine formula is now the operative UNOS/OPTN scoring system used for pediatric liver waitlist prioritization. Scores are calculated at listing and updated every 7–14 days. Higher scores correlate with higher 90-day waitlist mortality and higher urgency for transplant. The score is used for children who are under 12 years of age at the time of listing. Children ≥12 years use MELD (adult formula). A minimum value of 1.0 mg/dL is applied to creatinine, bilirubin, and albumin to prevent negative log values.

When to use

• At liver transplant listing for children with end-stage liver disease younger than 12 years
• Periodic updates of waitlist priority every 7–14 days (or more frequently during clinical deterioration)
• Clinical assessment of transplant urgency in pediatric hepatology consultations
• Research and audit of pediatric liver transplant outcomes
• Triage decisions in pediatric acute liver failure (when combined with King's College Criteria)
• Communication of prognosis to families during hepatic decompensation

Formula

Pearls & pitfalls

• Minimum values applied: total bilirubin ≥1.0 mg/dL, albumin ≥1.0 g/dL, INR ≥1.0, creatinine ≥1.0 mg/dL — values below these minimums are set to the minimum before the logarithm is calculated.
• Growth failure is defined as height or weight Z-score below −2 standard deviations for age and sex — this criterion requires documented anthropometric data.
• Children ≥12 years at listing use the adult MELD score (not PELD), so this calculator applies to children younger than 12.
• PELD is recalculated at each waitlist update — labs should be within 48 hours of submission for score updates. Albumin may have a longer acceptable window (30 days in some centers).
• The PELD score does NOT capture all prognostic dimensions in pediatric liver disease — disease-specific exceptions (hepatoblastoma, metabolic liver diseases like Wilson disease, primary hyperoxaluria) are assigned PELD exception points that may exceed the calculated PELD.
• Acute liver failure in children typically uses Status 1A/1B listing criteria rather than PELD score due to rapid deterioration — PELD score alone underestimates urgency in fulminant presentations.
• Serum creatinine in infants and toddlers is normally lower than in older children — age-specific normal ranges must be considered when interpreting creatinine values.
• The addition of creatinine to PELD improved the C-statistic for 90-day mortality prediction from 0.73 to 0.77 in validation cohorts.
• UNOS Policy 18 governs pediatric liver allocation — consult the current OPTN policy document for the most recent allocation algorithms, as policies are updated periodically.

Next steps

PELD ≤10: Lower urgency. Standard waitlist monitoring. Optimize medical management (nutrition, management of complications: ascites, encephalopathy, variceal bleeding). PELD 11–18: Moderate urgency. Close outpatient follow-up. Reassess liver function every 1–2 weeks. PELD 19–24: High urgency. Inpatient management or intensive outpatient monitoring. Consider PICU-level care if decompensating. PELD ≥25: Very high urgency. Urgent liver transplant evaluation. ICU admission if needed. Consider Status 1A/1B listing for fulminant liver failure. Listing Status 1A criteria: fulminant hepatic failure <8 weeks duration, no prior liver disease; Status 1B: children with chronic disease at high short-term risk.

Evidence

McDiarmid SV et al. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002;74(2):173-181. PMID:12151728. UNOS/OPTN Policy Update 2017 — incorporation of creatinine into PELD formula. Shneider BL et al. Pediatric hepatology and liver transplantation outcomes using PELD. Liver Transpl. 2012. OPTN data report: pediatric candidates and recipients awaiting liver transplant, 2010–2020.

References

1. McDiarmid SV et al. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002;74(2):173-181. — link
2. Shneider BL et al. Pediatric liver transplantation for metabolic disease: the impact of new allocation policy. Am J Transplant. 2007;7(8):2107-2113. — link
3. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Policy update: use of PELD for pediatric liver candidates. OPTN. 2017. — link
4. Squires JE et al. Pediatric acute liver failure. J Pediatr Gastroenterol Nutr. 2018;66(4):541-552. — link